The Cystic Fibrosis Foundation announced $1.7 million in new research funding to drive progress on its Path to a Cure. The awards, to seven academic institutions and two companies, will support focused research into key scientific challenges associated with developing therapies to address the underlying cause of disease for all people with CF, regardless of their underlying mutation.
McGowan Institute for Regenerative Medicine affiliated faculty member Adam Feinberg, PhD, Professor in the Departments of Biomedical Engineering and Materials Science and Engineering at Carnegie Mellon University, was one of the nine awardees. Dr. Feinberg will further develop and test a platform capable of overcoming the innate immune defenses in the lungs to successfully deliver a potential new genetic-based therapy to the airway epithelium, the tissue that lines the airways.
“There has been an explosion of scientific progress in novel technologies with the potential to benefit all people with CF, yet significant additional research will be required to move these advances out of the lab and safely to patients,” said William Skach, MD, executive vice president and chief scientific officer of the Cystic Fibrosis Foundation. “These awards reflect important investments into the foundational research that is needed to advance curative therapies for all people with cystic fibrosis.”
The Foundation is now accepting proposals for research funding in the 2021 calendar year. More information about funding opportunities is available on cff.org.
Congratulations, Dr. Feinberg!